Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290482 | 0.85 | TSHR (0.40) | KDM4EKMT2AALDH1A1LMNATSHR | |
| SCHEMBL10401661 | 0.78 | TSHR (0.42) | KDM4EGAAKMT2AALDH1A1TSHR | |
| Dexmedetomidine SCHEMBL22616265 | 0.78 | ADRA2A (0.42) | KMT2AALDH1A1LMNATSHRMAPT | |
| SCHEMBL9128752 | 0.77 | FAAH (0.30) | LMNATSHR | |
| SCHEMBL17745072 | 0.76 | ADRA2A (0.35) | TSHR | |
| SCHEMBL9647534 | 0.76 | ALDH1A1 (0.41) | KDM4EGAAKMT2AALDH1A1LMNA | |
| Medetomidine SCHEMBL22616184 | 0.76 | ADRA2A (0.43) | TSHRRAB9A | |
| Dexmedetomidine SCHEMBL22616211 | 0.76 | ADRA2A (0.43) | TSHRRAB9A | |
| Medetomidine SCHEMBL26432 | 0.76 | ADRA2A (0.50) | ATMTSHR | |
| Medetomidine SCHEMBL18497244 | 0.76 | ADRA2A (0.50) | ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3566703-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3566703-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3241553-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3241553-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2395999-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9555021-B2 | Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | ALLERGAN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160038466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9193690-B2 | Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | ALLERGAN, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080445-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120136035-A1 | 4-(1-(3-(HYDROXYMETHYL)-2-METHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | ALLERGAN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110301214-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLEGRAN, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010093910-A1 | 4-(1-(3-(HYDROXYMETHYL)-2-METHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | ALLERGAN, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | OPRK1, OPRM1, OPRD1 | KDM4E 1982/4885ATM 3152/4885GAA 1721/4885 |
| US-20110301214-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | OPRK1, OPRM1, OPRD1 | KDM4E 1982/4885ATM 3152/4885GAA 1721/4885 |
| US-20150080445-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | OPRK1, OPRM1, OPRD1 | KDM4E 1982/4885ATM 3152/4885GAA 1721/4885 |
| US-20120136035-A1 | 4-(1-(3-(HYDROXYMETHYL)-2-METHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | OPRK1, OPRD1, TPMT | KDM4E 1708/4885ATM 2458/4885GAA 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.